📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). (2025)

First Author: Fisher D

Attributed to: Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.2025.43.5_suppl.20

Publication URI: http://dx.doi.org/10.1200/jco.2025.43.5_suppl.20

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 5_suppl